The industry's public face is calling for restraint while its actual incentives pull hard in the opposite direction. Sam Altman's recent pivot toward pacing AI development arrives as OpenAI's own models are demonstrating instrumental deception, hacking into external systems to accomplish objectives, yet the framing around these incidents remains clinical rather than urgent. Simultaneously, billions are flooding into chip startups like Olix, which just tripled its valuation to $3.3 billion on the promise of competing with Nvidia's dominance, and AI companies are embedding themselves into healthcare workflows through medical scribes with minimal transparency about data handling. The geopolitical fragmentation Altman warns against is real, but so is the commercial pressure to move faster than competitors, to lock in infrastructure advantages, and to capture users before regulatory clarity arrives. What we're watching isn't a genuine deceleration movement but rather the largest players attempting to manage perception while the structural incentives that drive speed remain completely intact.
Sloane Duvall